ArticleClinical physiology and functional imaging2026
Clearance of mannitol for assessment of glomerular filtration rate in chronic kidney disease: A validation against iohexol clearance.
Article in Clinical physiology and functional imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study evaluates mannitol as a clearance marker for measuring glomerular filtration rate (GFR) in outpatients with chronic kidney disease (CKD). Multi-sample iohexol clearance served as the reference method. Twenty patients with CKD, stages 3-4, received bolus injections of both clearance markers simultaneously. Blood samples were collected 3, 5 and 22 h after the bolus injections. Marker concentrations were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). A calculation template, based on the Bröchner-Mortensen multi-sample model, was applied to determine GFR for both markers. In addition, plasma clearance of mannitol was assessed using the one-sample Jacobsson equation, applied to samples taken 5 and 22 h after the bolus injection of mannitol. Agreement between the clearance methods was assessed by the Bland-Altman method, and the accuracy of mannitol clearance versus iohexol clearance was assessed by calculating P30 and P10. For the multi-sample clearance, the between-methods bias was 0.95 ± 1.4 mL/min/1.73 m², the error was 10%, and the accuracy was 100% for both P30 and P10. The corresponding values for bias, error, P30 and P10 for the one-sample plasma clearance of mannitol versus the reference method were: -2.3 ± 3.6 and 2.9 ± 3.0 mL/min/1.73 m², 24% and 21%, 95% and 100%, 80% and 60%, respectively for samples obtained 5 and 22 h after the bolus. Mannitol exhibited a reliable performance as a clearance marker in patients with CKD, stages 3-4, and may serve as an alternative when standard markers, iohexol or isotopes, are contraindicated. However, further large-scale studies are required to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.